Aslan achieved ‘impressive’ overall response rate in BTC, says Piper Jaffray

Aslan Pharmaceuticals’ varlitinib added to gemcitabine and cisplatine achieved an “impressive” overall response rate of 43.8% and disease control rate of 93.8% in the Phase Ib/II study in first-line biliary tract cancer, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. Varlitinib was also well tolerated with the most common adverse events decreases in platelet and neutrophil counts, adds the analyst. The data presented last night increase his confidence in the fully-enrolled Phase III TreeTopp trial of varlitinib in second line biliary tract cancer with top-line data in the second half of 2019. He reiterates an Overweight rating on Aslan Pharmaceuticals with a $7 price target.
https://thefly.com/landingPageNews.php?id=2848605